Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Medical Tourism Experts

Analysis of: Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market (www.pipelinereview.com)
This will provide a strong challenge to US and EU companies planning biosimilars
Analysis of: Medical Errors Threatan One in 15 Hospitalized Children (www.healthcareitnews.com)
In the latest study released on Monday (April 7) in the journal "Pediatrics", researchers found a rate of 11 drug-related harmful events for every 100 hospitalized children.  That new number compares with an earlier estimate of only two per 100 hospitalized children based on traditional...
Analysis of: Amgen Drug Helps Bones (online.wsj.com)
Osteoporosis treatment is becoming highly competitive.  So how competitive is Denosumab's profile?
Analysis of: Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting (www.cyperus.com)
Leading consumer, employer and labor organizations have agreed with the top medical and health insurance groups on principles to govern the development of physician performance measures.  The "Patient Charter for Physician Performance Measurement, Reporting and Tiering Programs" creates a national...
Robert Forster, MD, Healthcare Consultant
Robert Forster, MD, Healthcare Consultant
Robert Forster, MD
Analysis of: Rx Watchdog Report: Trends in Manufacturer Prices of Brand Name Prescription Drugs Used by Medicare Beneficiaries—2002-2007 (www.aarp.org)
If I may, Mr. Goldstein suggests that education to providers re: cost/benefit or value will drive drug selection.  I disagree in that there are may barriers to provider (most physicians) behavior and their selection of drugs.  To mention a few are as follows:  1. My anecdotal experience...
Robert Forster, MD, Healthcare Consultant
Robert Forster, MD, Healthcare Consultant
Robert Forster, MD
Analysis of: DoJ joins whistle-blower suit against OH MDs, hospital (www.fiercehealthcare.com)
From the rather strick interpretration of Peter Stark's antitrust principles complied with mostly in the 1980's we have entered an era where rampent greed and highly sophisticated antitrust relationships exists in nearly of all hospitals especially with their own "dedicated" (read as owned)  multispecialty...
Analysis of: Special Report: Market Economy (www.rimag.com)
Retail chains are fast growing thanks to corresponding consumer purchasing power and increased disposable income however galloping the reality prices to disproportionate heights. Greater Retail chains are emerging in all countries more particularly most populated countries like India and Asian countries....
Robert Forster, MD, Healthcare Consultant
Robert Forster, MD, Healthcare Consultant
Robert Forster, MD
Analysis of: New Focus of Inquiry Into Bribes: Doctors (www.nytimes.com)
Illegal and unethical bribes to orthopedists have gone on since time immemorial and have been visible throughout the medical and device profession and business.  Yet little (despite Peter Robert Stark's attempt) to separate this added incentive from the most highly paid specialists in medicine,...
Richard Baland, Partner
Richard Baland, Partner
B2B CFO
Analysis of: Aging Baby Boomers Will Drive Demand for Healthcare Properties Over Next Decade, Grubb & Ellis Report Reveals (www.bio-medicine.org)
For one reason, this industry has outperformed the commercial average for the most recent eight years. Secondly, demographics are driving medical services. More of the population is aging. People are living longer. And Medical technology is improving at a rate that provides new and better healthcare...
Analysis of: Big Pharma rushing for foothold in emerging markets despite challenges (www.pipelinereview.com)
There are barriers to pharma companies in emerging markets, but if the companies want to make a few bucks, they do not have a choice.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 667

Analytics


Generated at 2009-01-07T19:00:58.307